Veracyte Inc.
VCYT | NASDAQ
$43.53
+$2.01 (+4.84%)
Sep 22, 2026, 2:45 PM ET · Market open
Company Profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Marc A. Stapley | Chief Executive Officer & Director |
| Rebecca Chambers | Executive Vice President & Chief Financial Officer |
| Steven French | Senior Vice President & Chief Information Officer |
| Annie McGuire | Executive VP, General Counsel & Head of Market Access |
| John Leite | Global Chief Commercial Officer |
| Jonathan Wygant | Vice President & Chief Accounting Officer |
| Karen Possemato | Senior Vice President of Corporate Marketing, Communications & Commercial Operations |
| Keith Gligorich | Senior Vice President of Global Operations |
| Kelly Gura | Director of Investor Relations |
| Kevin Richard Haas | Chief Development and Technology Officer |
| Phillip G. Febbo | Chief Scientific & Medical Officer |
| Tracy Ward | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Jul 31, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 4 | Filing |
Veracyte Inc.
| Country | United States |
| IPO Date | Oct 28, 2013 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 755 |
| CEO | Marc Stapley |
Contact Details
6000 Shoreline Court South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | VCYT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001384101 |
| CUSIP Number | 92337F107 |
| ISIN Number | US92337F1075 |
| SIC Code | 8071 |
Recent News
- 3 days ago / defenseworld.netSquarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT
- 5 days ago / defenseworld.netCorient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT
- 7 days ago / seekingalpha.comVeracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 8 days ago / globenewswire.comVeracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
- 13 days ago / gurufocus.comVeracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors
- 21 days ago / globenewswire.comVeracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- 27 days ago / zacks.comIs it Worth Adding Veracyte Stock to Your Portfolio Now?
- 28 days ago / zacks.comVCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
- 1 month ago / zacks.comDown 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround
- 1 month ago / seekingalpha.comVeracyte: Diagnostics With Favorable Economics
Add to Watchlist
Select watchlists to add or remove VCYT